InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | -1,020.00% |
| 10 | InMed Pharmaceuticals | 6.92 Mn | 1.68 Mn | - | -216.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.11% |
| Dec 31, 2025 | -9.83% |
| Sep 30, 2025 | -76.50% |
| Jun 30, 2025 | 721.59% |
| Mar 31, 2025 | 165.16% |
| Dec 31, 2024 | -17.07% |
| Sep 30, 2024 | 54.53% |
| Jun 30, 2024 | -48.80% |
| Mar 31, 2024 | -4.64% |
| Dec 31, 2023 | -171.02% |
| Sep 30, 2023 | -168.51% |
| Jun 30, 2023 | -348.26% |
| Mar 31, 2023 | 65.65% |
| Dec 31, 2022 | 164.03% |
| Sep 30, 2022 | -60.23% |
| Jun 30, 2022 | 113.33% |
| Mar 31, 2022 | -849.58% |
| Dec 31, 2021 | -178.81% |
| Sep 30, 2021 | 655.67% |
| Jun 30, 2021 | -49.48% |